Recent and Emerging Anti-seizure Drugs: 2013
Recent and emerging pharmacotherapies have become available for use within the last 4 years to enhance our ability to manage people with epilepsy (PWE). More antiseizure drug (ASD) choices allow greater opportunity to match a unique medicine with each patient from the time of first seizure and for drug-resistant epilepsy. Balancing the efficacy, safety, and tolerability of an ASD is unique for each person and epilepsy syndrome. This tailored approach to effectiveness includes seven new ASDs that have become available since 2009 to treat PWE expanding our armamentarium to more than two dozen ASDs in the US that are now available for use. “Which ASD is best?” is still a complex challenge that remains to be answered. Until the ASD is found that is a panacea for everyone, the role of new AEDs in the treatment of epilepsy lies in the hands of the clinician to address the overall needs of the person first and foremost. In this paper, the newest and emerging ASDs in 2013 are reviewed focusing on the pharmacology, efficacy, and adverse effects. Each ASD has benefits and risks and the ultimate role in clinical use will be established over time as experience with each agent grows.